These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34399998)

  • 1. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.
    Cheung P; Patel S; North SA; Sahgal A; Chu W; Soliman H; Ahmad B; Winquist E; Niazi T; Patenaude F; Lim G; Heng DYC; Dubey A; Czaykowski P; Wong RKS; Swaminath A; Morgan SC; Mangat R; Keshavarzi S; Bjarnason GA
    Eur Urol; 2021 Dec; 80(6):693-700. PubMed ID: 34399998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.
    Hannan R; Christensen M; Hammers H; Christie A; Paulman B; Lin D; Garant A; Arafat W; Courtney K; Bowman I; Cole S; Sher D; Ahn C; Choy H; Timmerman R; Brugarolas J
    Eur Urol Oncol; 2022 Apr; 5(2):216-224. PubMed ID: 34986993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.
    De B; Venkatesan AM; Msaouel P; Ghia AJ; Li J; Yeboa DN; Nguyen QN; Bishop AJ; Jonasch E; Shah AY; Campbell MT; Wang J; Zurita-Saavedra AJ; Karam JA; Wood CG; Matin SF; Tannir NM; Tang C
    BJU Int; 2022 May; 129(5):610-620. PubMed ID: 34228889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World.
    Gebbia V; Girlando A; DI Grazia A; Fazio I; Borsellino N; Piazza D; Serretta V; Pergolizzi S; Pontoriero A; Firenze A; Valerio MR
    Anticancer Res; 2020 Dec; 40(12):7037-7043. PubMed ID: 33288600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.
    Masini C; Iotti C; De Giorgi U; Bellia RS; Buti S; Salaroli F; Zampiva I; Mazzarotto R; Mucciarini C; Vitale MG; Bruni A; Lohr F; Procopio G; Caffo O; Nole F; Morelli F; Baier S; Buttigliero C; Ciammella P; Timon G; Fantinel E; Carlinfante G; Berselli A; Pinto C
    Eur Urol; 2022 Mar; 81(3):274-282. PubMed ID: 34602312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.
    Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T
    Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma.
    Franzese C; Marini B; Baldaccini D; Badalamenti M; Navarria P; Bellu L; Franceschini D; Comito T; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Lo Faro L; Tomatis S; Scorsetti M
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4411-4417. PubMed ID: 36109401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors.
    He L; Liu Y; Han H; Liu Z; Huang S; Cao W; Liu B; Qin Z; Guo S; Zhang Z; Lin M; Jiang X; Lin C; Li Y; Yao K; Dong P; Zhou F
    Am J Clin Oncol; 2020 Jan; 43(1):58-63. PubMed ID: 31651452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients.
    Ma MW; Li HZ; Gao XS; Liu MZ; Yin H; Yang KW; Chen JY; Ren XY; Wang D
    Curr Oncol; 2022 Oct; 29(10):7832-7841. PubMed ID: 36290896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group.
    Meyer E; Pasquier D; Bernadou G; Calais G; Maroun P; Bossi A; Theodore C; Albiges L; Stefan D; de Crevoisier R; Hennequin C; Lagrange JL; Grellard JM; Clarisse B; Licaj I; Habrand JL; Carrie C; Joly F
    Eur J Cancer; 2018 Jul; 98():38-47. PubMed ID: 29864737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.
    Hannan R; Christensen M; Christie A; Garant A; Pedrosa I; Robles L; Mannala S; Wang C; Hammers H; Arafat W; Courtney K; Bowman IA; Sher D; Ahn C; Cole S; Choy H; Timmerman R; Brugarolas J
    Eur Urol Oncol; 2022 Dec; 5(6):695-703. PubMed ID: 35985982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
    Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
    BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer.
    Doyle E; Killean AJ; Harrow S; Phillips ID
    Radiother Oncol; 2024 Jul; 196():110288. PubMed ID: 38648995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group.
    Franzese C; Marvaso G; Francolini G; Borghetti P; Trodella LE; Sepulcri M; Matrone F; Nicosia L; Timon G; Ognibene L; Vinciguerra A; Alongi F; Bortolus R; Corti L; Ramella S; Magrini SM; Livi L; Jereczek-Fossa BA; Scorsetti M; Arcangeli S
    Clin Exp Metastasis; 2021 Dec; 38(6):527-537. PubMed ID: 34748125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
    Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma.
    Barata PC; Mendiratta P; Kotecha R; Gopalakrishnan D; Juloori A; Chao ST; Koshkin V; Ornstein M; Gilligan TD; Wood LS; Rini BI; Angelov L; Garcia JA
    Clin Genitourin Cancer; 2018 Oct; 16(5):413-419.e1. PubMed ID: 30172552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study.
    Onal C; Oymak E; Guler OC; Tilki B; Yavas G; Hurmuz P; Yavas C; Ozyigit G
    Strahlenther Onkol; 2023 May; 199(5):456-464. PubMed ID: 36450836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease.
    Ramadan S; Quan K; Schnarr K; Juergens RA; Hotte SJ; Mukherjee SD; Kapoor A; Meyers BM; Swaminath A
    Acta Oncol; 2022 Jun; 61(6):705-713. PubMed ID: 35435129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
    Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
    Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.